Skip to main content

Search

Search the site:

News, Views, and Advocacy From the Oncology Nursing Society

News & Views

Advocacy

Stories

News & Views

Latest Articles
Clinical Practice
ONS News
ONS Leadership

Trending Topics

Research
Safety
COVID-19
Drug Reference Sheet
Special Populations
ONS Congress Newscast

View All Topics

Advocacy

Latest Articles
Get Involved

Stories View All

View All

ONS Members Tell Us About the Inspirational Nurses Who’ve Shaped Their Careers

Nurse well-being

ONS Members Tell Us About the Inspirational Nurses Who’ve Shaped Their Careers

November 23, 2023

Nurse Educator–Led Educational Fairs Help Reduce Hospital-Acquired Conditions

Oncology nurse education

Nurse Educator–Led Educational Fairs Help Reduce Hospital-Acquired Conditions

November 10, 2023

When the Nurse Coach Becomes the Client: How I Restored Balance and Set Goals on a Healing Journey

Oncology nurse influence

When the Nurse Coach Becomes the Client: How I Restored Balance and Set Goals on a Healing Journey

November 03, 2023

Filipino American History Month nurse standing next to flag

Nurse empowerment

Filipino American History Month Shines Light on the Contributions and Challenges of a Committed Community of Nurses

October 16, 2023

Explore Somatic Biomarker Testing Report Component Biomarker Testing

Clinical practice

Learn How to Read a Somatic Biomarker Testing Report

October 06, 2023

Search

News & Views

Advocacy

Stories

Home

Author Content

Cultural Competency

Health Disparities Have Cancer Implications for Indigenous People. Here’s How to Provide Culturally Competent Care.

Among all racial and ethnic groups, indigenous people (Native American and Alaska Natives) had the largest decline in life expectancy from 2020–2021. They also have the lowest overall life expectancy (65.2 years) than any of their Asian, Black, Hispanic, or White counterparts—in some cases, up to 20 years shorter. Indigenous people have disproportionately high rates of suicide, chronic liver disease, cardiac disorders, diabetes, and infant and maternal mortality.

September 14, 2023

U.S. Food and Drug Administration (FDA)

Focus on COVID-19 Prevention Intensifies for Patients With Cancer as FDA Removes Emergency Use Authorization for Evushield

On January 26, 2023 the U.S. Food and Drug Administration removed its emergency use authorization of tixagevimab/cilgavimab (Evushield) for the prevention of SARS-CoV-2 infection after exposure to the virus. FDA said it made the decision because the agent is not effective in preventing infections from the current variants that are responsible for 90% of today’s infections and because the risks of the drug’s side effects do not outweigh the benefits.

January 30, 2023

Nursing Considerations for Adolescent and Young Adult Cancer Survivorship Care

Adolescent and young adults (AYAs)—those diagnosed between the ages of 15 and 39—comprise about 5% of all annual cancer diagnoses. The population has unique challenges that must be considered as part of patient-centered survivorship care planning.

December 13, 2021

Nursing Considerations for Melanoma Survivorship Care

Breast, prostate, colorectal, and melanoma are the most common primary cancer sites among 58% of survivors. Advancements in immunotherapy and targeted therapies have significantly increased treatment options for a disease that once had very limited treatment options, markedly improving overall five-year survival rates for patients with melanoma. Yet survival rates vary depending on extent of disease (local versus metastatic) and ethnic minority disparities. Although the overall (all stages combined) five-year survival rate for White patients with melanoma is 93%, the rate drops to 87% for Hispanics and to just 23% for those with distant melanoma.

Nursing Considerations for Lymphoma Survivorship Care

As treatments have advanced and patients and providers have more options, cure and survivorship rates for lymphomas are improving: five-year survival rates for Hodgkin and non-Hodgkin lymphoma are 86% and 71%, respectively. Despite good results from treatment, research indicates that lymphoma survivors carry a significant amount of late and chronic effects. Even in a complete remission, late effects of treatment present a burden for patients' physical and psychosocial well-being.

February 04, 2021

nursing professional development

Lifelong Learning and Professional Development Are Crucial to Patient Outcomes

Cancer care is always changing, new science is constantly developing, and oncology nurses must work to keep up. ONS’s philosophy is that every nurse has room to develop knowledge, practice, and research. As an organization, we embody a commitment to lifelong learning and professional development because we understand that both are crucial to oncology nursing and patient outcomes.

January 18, 2021

Non-Small Cell Lung Cancer Prevention, Screening, Diagnosis, Treatment, Side Effects, and Survivorship

Lung cancer is the leading cause of cancer death in the United States, accounting for about one quarter of cancer deaths, and more than a quarter of million lung cancer diagnoses are projected in the United States for 2020. Lung cancer has various types, pathologies, and histologies, each with its own prognosis and treatment plan. Non-small cell lung cancer consists of about 80%–85% of lung cancer diagnoses.

November 05, 2020

Clinical practice

Non-Hodgkin Lymphoma Symptoms, Diagnosis, Treatment, and Survivorship Recommendations

Lymphomas are hematologic malignancies, specifically of the lymphatic system. They are classified into two types: Hodgkin and non-Hodgkin (NHL). NHL is the seventh most common cancer in the United States and Hodgkin seen much less frequently as the 26th, but new treatment options have improved survival rates.

September 29, 2020

Clinical practice

Oncology Drug Reference Sheet: Rucaparib

Rucaparib (Rubraca^®) has U.S. Food and Drug Administration approval for both maintenance and treatment indications in gynecologic cancers. It originally received accelerated approval in 2016 for the treatment of deleterious, BRCA variant–associated advanced ovarian cancer that has failed two or more chemotherapies. In 2018, it was approved for maintenance therapy of various gynecologic malignancies. Most recently, rucaparib received approval for BRCA-positive metastatic castration-resistant prostate cancer treatment after androgen-directed and chemotherapy.

August 25, 2020

Myeloproliferative Neoplasm Symptoms, Diagnosis, Treatment, and Survivorship Recommendations

Myeloproliferative neoplasms are a group of blood cancers that start with a small mutation in the stem cells of the bone marrow. Although MPNs are quite rare, essential thrombocythemia, polycythemia vera, and myelofibrosis are the most common types. Each represents a mutation of a different source of stem cell.

Cancer Consortium Report Reveals High Mortality Rates in Patients With COVID-19 and Cancer

Patients with cancer who contracted the COVID-19 coronavirus had high rates of 30-day all-cause mortality that was associated with general risk factors and risk factors unique to cancer, according to findings from one of the first data registry reports of patients with the dual diagnoses. The results were published in Lancet.

Melanoma Prevention, Screening, Treatment, and Survivorship Recommendations

It is no coincidence that May is Melanoma Awareness Month. As Americans take to the great outdoors, they also must take caution to protect their skin and prevent melanoma.

Psychosocial Support for Patients With Cancer During COVID-19

When the COVID-19 novel coronavirus pandemic hit the United States, in a matter of days clinicians were scrambling to find novel ways to screen, triage, and provide telehealth interventions to protect patients with chronic conditions who are especially vulnerable to COVID-19. As nurses, we are accustomed to helping patients in crisis acclimate to a changing environment, process large amounts of information, and have their psychosocial needs met.

Cancer screening

Colorectal Cancer Prevention, Screening, Treatment, and Survivorship Recommendations

Colorectal cancer (CRC) is the third most common cancer affecting men and women in the United States. When CRC is found at an early stage before it has spread, the five-year relative survival rate is about 90%, yet it remains a leading cause of cancer-related death among both genders.

Clinical practice

COVID-19 Fact Sheet and Implications for Patients With Cancer

COVID-19 is a novel coronavirus (a large family of viruses that can cause cold-like illnesses) first identified in December 2019. It is a respiratory illness and can be spread from person to person through respiratory droplets during close contact. The first case of COVID-19 in the United States was reported on January 21, 2020.

Prostate cancer

Prostate Cancer Prevention, Screening, Treatment, and Survivorship Recommendations

One in nine men will be diagnosed with prostate cancer, the second leading cause of death in men in the United States. Survival varies greatly depending on the disease’s severity and extent at diagnosis: five-year survival rates are near 100% for local or regional disease, but they drop to 30% for metastatic prostate cancer.

January 27, 2020

U.S. Food and Drug Administration (FDA)

Plan Ahead to Ensure Consistency in Patient Care and Communication During Drug Shortages

A manufacturing delay leading to a shipping delay caused the October 2019 vincristine shortage, according to a letter Pfizer sent to its customers on October 18; the U.S. Food and Drug Administration first reported the shortage on October 16. It affects both the 1 mg/ml and 2 mg/2 ml single-dose ONCO-TAIN™ glass fliptop vials.

October 22, 2019

Oncology Drug Reference Sheet: Darolutamide

Based on the results of the phase III ARAMIS trial that demonstrated significant improvement in metastasis-free survival, the U.S. Food and Drug Administration approved darolutamide under priority review on July 30, 2019. Darolutamide is approved for nonmetastatic, castration-resistant prostate cancer in men receiving concurrent gonadotropin-releasing hormone therapy or who have had bilateral orchiectomy.

October 22, 2019

U.S. Food and Drug Administration (FDA)

FDA Rolls Out More New Indications for Existing Agents

Pembrolizumab, lenalidomide, and avelumab all received new treatment indications in spring 2019. Here’s what you need to know about dosing, adverse events, and other nursing considerations for these and other drugs that the U.S. Food and Drug Administration (FDA) approved from April–June 2019.

September 25, 2019

U.S. Food and Drug Administration (FDA)

FDA’s Latest Approved Drugs and Indications Include Two Oral Agents

Because two oral therapies received new indications in the U.S. Food and Drug Administration’s (FDA’s) most recent round of approvals, oncology nurses will want to focus on ways to manage patients in the home. Assessing oral adherence, encouraging patients to report adverse events, and ensuring their understanding of complex dosing regimens are critical components of nursing care. ONS offers an oral adherence toolkit and oral chemotherapy patient education sheets to help with patient management.

Clinical practice

Oncology Drug Reference Sheet: Cabozantinib

Cabozantinib (Cabometyx^®) received an additional U.S. Food and Drug Administration (FDA)-approved indication in January 2019 for use in patients with hepatocellular carcinoma (HCC) who have already been treated with sorafenib. It received prior approval for the treatment of renal cell carcinoma in 2017. The research leading to the approval in the HCC setting showed improved overall survival, progression-free survival, and overall response in the cabozantinib treatment arm.

Care coordination

Oncology Urgent Care Clinics Are an Emerging Setting for Cancer Care Delivery

Patients with cancer are living longer, embarking on complex treatment regimens, and experiencing more complications associated with care. As a result, a large volume of patients with cancer require urgent or emergency visits throughout their disease trajectory. Although the need remains constant, what has evolved over time are the chief complaints that bring patients in, the care associated with complications, and new options to lower the burden and cost of care.

Genetics & genomics

Biosimilars, Oral Agents, and Drugs Targeting Genetic Mutations Are Creating a Paradigm Shift in Cancer Treatment

New treatment options continue to emerge for diseases that until recently had limited, if any, treatment choices. Nurses are seeing more changes in the way treatment regimens come together, biosimilars are presenting viable options for patients, and genetic mutations, as opposed to disease sites, are at the forefront of drug development.

U.S. Food and Drug Administration (FDA)

Biosimilars and Oral Agents Lead New Approvals in the Cancer Setting

A majority of the U.S. Food and Drug Administration (FDA) approvals for cancer agents in the latter part of 2018 represented second and third approvals for new indications in other disease sites. Many were given expedited approval, but with that comes the potential that the incidence of adverse events may be underrepresented because fewer patients received the agents in a clinical trial setting.

December 18, 2018

Chemotherapy Is Still a Staple in Treatment Plans. Here’s a Fresh Look at a Familiar Treatment Option

Despite all of the new drugs approved in recent years—particularly immunotherapies, oral agents, and biosimilars—that have forced nurses to consider many novel approaches to patient care, the importance of chemotherapy in cancer treatment has remained a constant. In a field where it feels like no two days are the same and new drugs emerge on a rolling basis, chemotherapy continues to be a staple in cancer treatment plans and safety and administration principles remain constant.

November 26, 2018

Current page 1
Page 2
Page 3
Next page
Last page

To discuss the information in this article with other oncology nurses, visit the ONS Communities.

To report a content error, inaccuracy, or typo, email pubONSVoice@ons.org.

Kathleen Wiley MSN, RN, AOCNS®

News, Views, and Advocacy From the Oncology Nursing Society

Legal Notices

Contact Us

Conferences

Advertising

Newsroom

Sitemap

Oncology Nursing Foundation

© Copyright 2023 Oncology Nursing Society

Back to Top ▲